Johnson & Johnson (JNJ): what the price requires

At today's price, Johnson & Johnson (JNJ) is priced for today's economics sustained for ~8.5 years. boothcheck doesn't publish a fair value or a price target; it shows what the price assumes, so you can judge whether that bar is too high.

Generated: 2026-07-13 · Source: https://boothcheck.com/report/JNJ

Headline

What The Price Requires (Inversion)

The assumption today's price embeds, recovered by inverting the valuation.

Solve inputs: computed at a 7.1% cost of capital; growth searched up to the 25% self-funding ceiling; each 1pp moves the implied horizon ~3.6 years.

Reconcile: at the x-ray's 9.3% required return this reads ~14.9 years; the models below use their own rates.

How unusual the bet is: high

Valuation X-Ray

Asset, earnings-power and peer-multiple models all land far below the price; ONLY the growth-DCF reaches it. The bet is durable compounding the static frames structurally cannot price (a moat/durability premium).

How the valuation models price the stock relative to the market price. Price/FV above 1.0 means the market pays more than that lens defends (expensive); at or below 1.0 the lens can defend the price.

Families that justify the price: Growth Families that call it expensive: Asset, Earnings

The models below discount at their own flat-beta convention rates (cost of equity 9.3%, WACC 8.5%); the inversion above states its own rate.

Per-Model Detail (n=15)

Solvency

Operating profit is negative or near zero and the company has no demonstrated through-cycle (mid-cycle) operating margin to normalize against, so years-to-repay cannot be computed honestly.

Operating profit is negative or near zero and there is no demonstrated through-cycle (mid-cycle) operating margin to normalize against, so interest coverage cannot be computed honestly.

Bullet Takeaways

• Johnson & Johnson is two large franchises under one roof, a drug business led by oncology and immunology and a medical-device business in cardiovascular, surgery, orthopaedics, and vision, and the recent growth is being carried by a handful of oncology drugs offsetting a steep decline in its old immunology anchor.
• The defining risk is patent math: Immunology sales fell 11.8% to $15.7 billion in 2025 as STELARA lost exclusivity, and DARZALEX, now a $4 billion-a-quarter oncology engine, faces its own US patent expirations in 2029.
• The next things to watch are oncology launch curves, with CARVYKTI growing 87.6% year over year to $286 million and DARZALEX up 18%, against an unresolved talc litigation overhang that the company is still working through the courts.

Bull Case

Look at where the earnings are moving, because the trajectory is more interesting than the steady-compounder reputation suggests. Reported first-quarter sales grew 9.9% to $24.1 billion, and crucially that growth came while the company was absorbing the loss of its largest immunology drug. Innovative Medicine sales reached $15.4 billion on 7.4% operational growth, and the company raised full-year 2026 guidance to roughly $100.8 billion in sales and $11.55 in adjusted EPS at the midpoint. A business growing through a major patent cliff rather than shrinking into one is demonstrating that its new portfolio is bigger than the hole left by the old.

The oncology engine doing the lifting is real and accelerating. DARZALEX led with 18% growth, reaching $4 billion in quarterly sales, and the 10-K confirms the underlying franchise economics, noting J&J pays Genmab a royalty of "12% to 20% of total DARZALEX net sales", royalties that totaled $2.4 billion in fiscal 2025, a back-of-envelope confirmation of a roughly $13 to $20 billion annual product. CARVYKTI, the cell therapy partnered with Legend, grew 87.6% to $286 million with 53.2% sequential growth, the shape of a launch still early in its curve. These are not legacy products defending share; they are new mechanisms expanding into earlier treatment lines.

Underneath the drug story sits a device business and a fortress balance sheet that fund the next wave. MedTech grew 4.6% operationally to $8.6 billion, with the 10-K describing a broad portfolio across "cardiovascular, orthopaedics, surgery, and vision" and an Orthopaedics franchise of $9.3 billion. Interest coverage of 23.5 times and net debt of about 1.5 times operating income give J&J the capacity to keep funding R&D and dealmaking through any single year's setbacks, and the share count has been shrinking about 2.1% a year while the company raised its dividend again. This is a company that can lose a blockbuster and keep compounding because it has the pipeline and the cash to replace it.

Bear Case

The price leans on a specific future revenue stream holding up, and the most fragile assumption is that the oncology drugs replacing today's expiring blockbusters do so on schedule and on size. The cautionary template is already in the numbers: Immunology sales declined 11.8% to $15.7 billion in 2025, "primarily due to the decline of STELARA" losing exclusivity, a single drug erasing nearly $2 billion of high-margin revenue in a year. That is what a patent cliff does, and it is not a one-time event. The same 10-K notes DARZALEX's core US patents "both expire in the United States in 2029", which means the $4 billion-a-quarter oncology anchor now carrying the company has a visible end date on its exclusivity. The bull case rests on the next generation arriving before the current one fades; the bear case is that drug development does not run on a reliable timetable, and the gaps between cliffs and launches are where the earnings get exposed.

The second fragility is the talc overhang, which refuses to resolve cleanly. The company's own disclosures describe litigation marked by "the uncertainty and unpredictability of the number of potential claims" and the difficulty of achieving comprehensive multi-party settlements. With tens of thousands of claims consolidated and the company's repeated attempts to resolve the matter through bankruptcy having collapsed, J&J is back to defending individual cases, which means the ultimate cost remains a range rather than a number. For a stock priced as a low-risk compounder, an open-ended legal liability that the company cannot put a ceiling on is exactly the kind of tail the valuation does not obviously pay for.

Then there is what the price asks. The market is paying a premium that the medical-device franchise must justify by holding its growth at a high rate for the better part of a decade, and the static valuation methods do not get there. The earnings-power lens, which values the business on its current sustainable profit without growth, sits at less than half of today's price, and the asset-value methods read it as expensive too. Only the peer-multiple and growth-DCF approaches reach the price. That is the signature of a stock priced for durable growth, not for current earnings, and the durability is precisely what the patent calendar and the litigation calendar both threaten.

Valuation

The cleanest way to read this price is through the device business, because that is the segment carrying the premium. The market is paying for MedTech's operating growth to hold at roughly its self-funding ceiling for about eight years, a long runway to underwrite for a mature medical-device franchise. That is the bet in one sentence: not a sudden acceleration, but durability of above-average growth sustained far longer than most franchises manage.

The valuation methods split into two camps that say opposite things. Peer-multiple and growth-DCF approaches land at or above today's price and justify it. The earnings-power and asset-value methods land well below it, with the zero-growth earnings lens sitting at roughly a third of the price. That spread is the whole story: value J&J on what it earns today and the price looks rich; value it on what comparable healthcare names fetch and on credited future growth, and the price is defensible. A reader should take from the pattern that this is a growth-and-quality premium, not a price supported by current cash generation alone, which raises the stakes on the pipeline executing.

The balance sheet removes solvency from the worry list. Net debt of about $37 billion is roughly 1.5 times trailing operating income, interest coverage runs at 23.5 times, and the company holds $22 billion of liquid assets against its obligations. The genuine downside here is not financial fragility; it is the combination of patent timing and an open-ended talc liability the disclosures explicitly decline to bound. Those are the variables that move the bet, not the leverage.

Catalysts

The first-quarter report was a clear positive. J&J posted reported sales of $24.1 billion, up 9.9%, with adjusted EPS of $2.70, and raised full-year 2026 guidance to roughly $100.8 billion in sales and $11.55 adjusted EPS at the midpoint, while hiking the dividend. The oncology franchise drove it: DARZALEX up 18% to $4 billion, CARVYKTI up 87.6% to $286 million with 53.2% sequential growth, plus contributions from ERLEADA and RYBREVANT/LAZCLUZE.

Recent pipeline progress adds to the launch story, including approvals for ICOTYDE in plaque psoriasis and TECVAYLI plus DARZALEX FASPRO as early as second-line in relapsed or refractory multiple myeloma, alongside CARVYKTI's expansion into earlier treatment lines. The catalysts to watch are the launch trajectories of these oncology assets, since they must collectively outgrow the coming DARZALEX and remaining immunology exclusivity losses, and any movement in the talc litigation. As of June 2026 more than 68,000 claims were consolidated and the company's latest bankruptcy-based resolution effort had collapsed, leaving it to defend cases individually, so any settlement framework or adverse verdict is a direct swing factor on the stock.

Peer Cohorts (Per Segment, With Filing Citations)

Innovative Medicine (reported)

• ABBV (AbbVie Inc.)
• (no filing in the citation store)
• LLY (ELI LILLY & Co)
• (no filing in the citation store)
• BMY (Bristol-Myers Squibb Company)
• (no filing in the citation store)
• PFE (Pfizer Inc.)
• (no filing in the citation store)

MedTech (reported)

• PFE (Pfizer Inc.)
• (no filing in the citation store)
• MRK (Merck & Co., Inc.)
• (no filing in the citation store)
• ABBV (AbbVie Inc.)
• (no filing in the citation store)
• BMY (Bristol-Myers Squibb Company)
• (no filing in the citation store)
• NVS (Novartis AG)
• (no filing in the citation store)
• GSK (GSK plc)
• (no filing in the citation store)
• AZN (ASTRAZENECA PLC)
• (no filing in the citation store)
• LLY (ELI LILLY & Co)
• (no filing in the citation store)

Methodology Note

• Priced-in inversion: the valuation is inverted on the current price to recover the operating-income growth, duration, and steady-state margin the price embeds (ROE for financials, FFO growth for REITs).
• Valuation x-ray: the valuation models, grouped into four families (asset, earnings, relative, growth). Each model is expressed as a price/FV ratio (distance from price), not a point fair-value estimate. The spread across families is the disagreement.
• Solvency: net cash/debt, net-debt-to-NOPAT, interest coverage, and share-count CAGR from EDGAR financials (net debt / FFO and fixed-charge coverage for REITs; regulatory-capital framing for financials).
• Peer cohorts: per-segment comparables with deep-linkable SEC filing citations.

Fundamentals sourced from SEC EDGAR filings. Current price from Databento. The priced-in inversion and valuation x-ray are computed by the boothcheck engine; narrative composed by AI from the structured data.